Results 151 to 160 of about 1,455 (196)

VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies. [PDF]

Int J Mol Sci
Corrao S, Moschetti M, Scibetta S, Calvo L, Giardina A, Cangemi I, Zizzo C, Colomba P, Duro G.   +8 more
europepmc   +1 more source

Erythematous Plaques and Systemic Inflammation in VEXAS Syndrome. [PDF]

Dtsch Arztebl Int
Ruffer N, Krusche M, Determann O.
europepmc   +1 more source

Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review. [PDF]

EClinicalMedicine
Efficace F, Krepper D, Sparano F, Fazi P, Voso MT, Gurnari C.   +5 more
europepmc   +1 more source

In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. [PDF]

Nat Commun
Mizumaki H, Gao S, Wu Z, Gutierrez-Rodrigues F, Bissa M, Feng X, Groarke EM, Li H, Alemu L, Raffo DQ, Darden I, Kajigaya S, Grayson PC, Franchini G, Young NS, Patel BA.   +15 more
europepmc   +1 more source

Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience. [PDF]

Br J Haematol
Heiblig M, Plesa A, Tantot J, Jamilloux Y, Labussière-Wallet H, Sujobert P.   +5 more
europepmc   +1 more source

Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome.

JAMA Dermatol
Grolleau C, Battistella M, Zakine E, Poisot T, Cordoliani F, Mahevas T, Jachiet M, de Masson A, Mekinian A, Terrier B, Lavialle SG, Fenaux P, Adès L, Zhao LP, Serror K, Duchmann M, Clappier E, Onifarasoaniaina R, Le Buanec H, Moguelet P, Bouaziz JD, Chasset F, FRENVEX Group.   +22 more
europepmc   +1 more source